Author:
Varughese Bijo,Madrewar Dnyanoba,Polipalli Sunil Kumar,Kapoor Seema
Publisher
Springer Science and Business Media LLC
Reference43 articles.
1. Vernon HJ. Inborn errors of metabolism: advances in diagnosis and therapy. JAMA Pediatr. 2015;169:778–82.
2. Almannai M, Marom R, Sutton VR. Newborn screening: a review of history, recent advancements, and future perspectives in the era of next generation sequencing. Curr Opin Pediatr. 2016;28:694–9.
3. Levy HL, Shih VE, Madigan PM, MacCready RA. Transient tyrosinemia in full-term infants. JAMA. 1969;209:249–50.
4. Tanguay RM, Valet JP, Lescault A, Duband JL, Laberge C, Lettre F, et al. Different molecular basis for fumarylacetoacetate hydrolase deficiency in the two clinical forms of hereditary tyrosinemia (type I). Am J Hum Genet. 1990;47:308–16.
5. Mak CM, Lam C-W, Chim S, Siu T-S, Ng K-F, Tam S. Biochemical and molecular diagnosis of tyrosinemia type I with two novel FAH mutations in a Hong Kong chinese patient: recommendation for expanded newborn screening in Hong Kong. Clin Biochem. 2013;46:155–9.